Atara Biotherapeutics (ATRA) Competitors $10.42 +0.07 (+0.68%) (As of 11:33 AM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends ATRA vs. FULC, ACB, FATE, LXEO, DMAC, ZNTL, ATAI, TNYA, ACRS, and ACRVShould you be buying Atara Biotherapeutics stock or one of its competitors? The main competitors of Atara Biotherapeutics include Fulcrum Therapeutics (FULC), Aurora Cannabis (ACB), Fate Therapeutics (FATE), Lexeo Therapeutics (LXEO), DiaMedica Therapeutics (DMAC), Zentalis Pharmaceuticals (ZNTL), Atai Life Sciences (ATAI), Tenaya Therapeutics (TNYA), Aclaris Therapeutics (ACRS), and Acrivon Therapeutics (ACRV). These companies are all part of the "pharmaceutical products" industry. Atara Biotherapeutics vs. Fulcrum Therapeutics Aurora Cannabis Fate Therapeutics Lexeo Therapeutics DiaMedica Therapeutics Zentalis Pharmaceuticals Atai Life Sciences Tenaya Therapeutics Aclaris Therapeutics Acrivon Therapeutics Fulcrum Therapeutics (NASDAQ:FULC) and Atara Biotherapeutics (NASDAQ:ATRA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, profitability, community ranking, valuation, dividends and risk. Does the media favor FULC or ATRA? In the previous week, Fulcrum Therapeutics had 2 more articles in the media than Atara Biotherapeutics. MarketBeat recorded 5 mentions for Fulcrum Therapeutics and 3 mentions for Atara Biotherapeutics. Atara Biotherapeutics' average media sentiment score of 0.97 beat Fulcrum Therapeutics' score of 0.80 indicating that Atara Biotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fulcrum Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Atara Biotherapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend FULC or ATRA? Fulcrum Therapeutics presently has a consensus price target of $9.33, suggesting a potential upside of 105.58%. Atara Biotherapeutics has a consensus price target of $16.67, suggesting a potential upside of 61.03%. Given Fulcrum Therapeutics' higher probable upside, equities research analysts plainly believe Fulcrum Therapeutics is more favorable than Atara Biotherapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Fulcrum Therapeutics 1 Sell rating(s) 6 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.20Atara Biotherapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.60 Which has more volatility and risk, FULC or ATRA? Fulcrum Therapeutics has a beta of 2.14, suggesting that its stock price is 114% more volatile than the S&P 500. Comparatively, Atara Biotherapeutics has a beta of 0.55, suggesting that its stock price is 45% less volatile than the S&P 500. Do institutionals & insiders believe in FULC or ATRA? 89.8% of Fulcrum Therapeutics shares are held by institutional investors. Comparatively, 70.9% of Atara Biotherapeutics shares are held by institutional investors. 4.1% of Fulcrum Therapeutics shares are held by insiders. Comparatively, 3.7% of Atara Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Does the MarketBeat Community believe in FULC or ATRA? Atara Biotherapeutics received 335 more outperform votes than Fulcrum Therapeutics when rated by MarketBeat users. Likewise, 67.45% of users gave Atara Biotherapeutics an outperform vote while only 61.25% of users gave Fulcrum Therapeutics an outperform vote. CompanyUnderperformOutperformFulcrum TherapeuticsOutperform Votes9861.25% Underperform Votes6238.75% Atara BiotherapeuticsOutperform Votes43367.45% Underperform Votes20932.55% Which has higher earnings and valuation, FULC or ATRA? Fulcrum Therapeutics has higher earnings, but lower revenue than Atara Biotherapeutics. Fulcrum Therapeutics is trading at a lower price-to-earnings ratio than Atara Biotherapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFulcrum Therapeutics$80.87M3.03-$97.33M-$0.31-14.65Atara Biotherapeutics$100.44M0.59-$276.13M-$25.78-0.40 Is FULC or ATRA more profitable? Fulcrum Therapeutics has a net margin of 0.00% compared to Atara Biotherapeutics' net margin of -132.58%. Atara Biotherapeutics' return on equity of 0.00% beat Fulcrum Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Fulcrum TherapeuticsN/A -7.31% -6.74% Atara Biotherapeutics -132.58%N/A -90.16% SummaryFulcrum Therapeutics beats Atara Biotherapeutics on 11 of the 19 factors compared between the two stocks. Ad The Tomorrow InvestorThis drone stock is setting up to transform medical supply deliveryDrone stocks are on a tear, with certain symbols seeing gains as high as 300% over just a matter of weeks.Click here to see how a new partnership could catapult this drone suppliers' growth Get Atara Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATRA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATRA vs. The Competition Export to ExcelMetricAtara BiotherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$59.62M$2.98B$5.18B$9.31BDividend YieldN/A1.85%4.78%4.06%P/E Ratio-0.4045.47130.2217.53Price / Sales0.59420.221,246.14139.51Price / CashN/A182.1341.2337.95Price / Book-0.433.924.884.92Net Income-$276.13M-$42.03M$119.65M$225.78M7 Day Performance-11.91%-3.37%16.62%-1.56%1 Month Performance-8.65%7.95%16.34%6.68%1 Year Performance-27.69%21.00%35.38%22.48% Atara Biotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATRAAtara Biotherapeutics3.7429 of 5 stars$10.42+0.7%$16.67+59.9%-31.0%$60.02M$100.44M-0.40165Gap UpFULCFulcrum Therapeutics1.8866 of 5 stars$4.42+11.6%$9.33+111.2%-15.8%$238.41M$80.87M-13.68100Positive NewsACBAurora Cannabis0.2987 of 5 stars$4.29-0.5%N/A-6.9%$235.26M$200.35M-5.671,073FATEFate Therapeutics3.7124 of 5 stars$2.05+12.0%$6.75+229.3%-37.7%$233.48M$13.45M-1.22550Short Interest ↑LXEOLexeo Therapeutics3.0452 of 5 stars$6.99+1.6%$23.80+240.5%-44.4%$231.13M$650,000.00-2.1858Positive NewsDMACDiaMedica Therapeutics2.9903 of 5 stars$5.37-0.2%$7.00+30.4%+89.1%$229.62MN/A-9.6120Short Interest ↓News CoverageZNTLZentalis Pharmaceuticals2.5782 of 5 stars$3.22+4.2%$10.00+210.6%-78.7%$229.46MN/A-1.24160ATAIAtai Life Sciences3.0279 of 5 stars$1.34-1.5%$9.00+571.6%+4.8%$224.86M$331,000.00-1.6883Positive NewsTNYATenaya Therapeutics4.0319 of 5 stars$2.82+2.5%$17.33+514.7%-32.2%$223.40MN/A-1.91110Analyst ForecastNews CoverageACRSAclaris Therapeutics3.7795 of 5 stars$3.06-5.0%$8.80+187.6%+222.8%$218.58M$31.25M-6.1986ACRVAcrivon Therapeutics1.4082 of 5 stars$7.02-0.6%$23.67+237.1%+57.1%$218.58MN/A-2.6158 Related Companies and Tools Related Companies FULC Alternatives ACB Alternatives FATE Alternatives LXEO Alternatives DMAC Alternatives ZNTL Alternatives ATAI Alternatives TNYA Alternatives ACRS Alternatives ACRV Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ATRA) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersThis drone stock is setting up to transform medical supply deliveryDrone stocks are on a tear, with certain symbols seeing gains as high as 300% over just a matter of weeks.The Tomorrow Investor | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredHealthcare Takes A Big Step Forward With The Help of A.I.To date, we've seen baseline AI models lay the groundwork. Tools like ChatGPT are useful, but they are still s...Wall Street Star | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atara Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Atara Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ATRA Stock Alerts